GLP-1 Medications · Tool Face-Off

Semaglutide vs Tirzepatide

Quick answer

Both are blockbuster weight-loss and diabetes drugs, but Tirzepatide's dual-action mechanism edges out Semaglutide on raw efficacy. Semaglutide is older, cheaper, and has more long-term data — making it the safer 'starter' choice for most people.

Our pick

Semaglutide

The OG GLP-1 — proven, widespread, and the drug that started the cultural moment

4.3★

Tirzepatide

The overachiever — hits two receptors and delivers class-leading weight loss

4.1★

Mechanism

GLP-1 receptor agonist (single)

GLP-1 + GIP dual receptor agonist

Brand Names

Ozempic (diabetes), Wegovy (obesity)

Mounjaro (diabetes), Zepbound (obesity)

Avg. Weight Loss (clinical trials)

~15% body weight (Wegovy STEP trials)

~20-22% body weight (SURMOUNT trials)

A1C Reduction

~1.5-1.8%

~2.0-2.3%

Dosing Schedule

Once weekly injection

Max Approved Dose

2.4 mg/week (obesity); 2.0 mg (diabetes)

15 mg/week

List Price (monthly, brand)

~$900-$1,000 (Wegovy/Ozempic)

~$1,000-$1,100 (Zepbound/Mounjaro)

Generic / Compounded Availability

Compounded widely available; generic coming ~2026

Compounded available (shortage resolved); generic later

Proven Cardiovascular Benefit

Yes — SELECT trial: 20% reduction in MACE

Promising data (SURMOUNT-MMO); full results pending

Years on Market

~6 years (Ozempic since 2017)

~2 years (Mounjaro since 2022)

Common Side Effects

Nausea, vomiting, constipation, diarrhea

Nausea, vomiting, constipation, diarrhea (similar profile)

FDA-Approved for Heart Failure (HFpEF)

Yes — Zepbound approved 2024

Semaglutide

Long-Term Data★★★★★

Dosing Convenience★★★★½

Blood Sugar Control★★★★½

Cost & Accessibility★★★½☆

Weight Loss Efficacy★★★★☆

Side Effect Tolerance★★★½☆

Cardiovascular Benefit★★★★★

Tirzepatide

Long-Term Data★★★½☆

Dosing Convenience★★★★½

Blood Sugar Control★★★★★

Cost & Accessibility★★★☆☆

Weight Loss Efficacy★★★★★

Side Effect Tolerance★★★½☆

Cardiovascular Benefit★★★★☆

Worth knowing

Tirzepatide beat Semaglutide head-to-head in the SURPASS-2 trial for both A1C reduction and weight loss.
Semaglutide's SELECT trial enrolled 17,000+ patients with cardiovascular disease — the cardiovascular benefit is rock-solid.
Both drugs can cause a rare but serious risk of pancreatitis and should be avoided with a personal/family history of MTC (thyroid cancer).
Compounded versions of both drugs surged during shortages, but the FDA has warned about quality and dosing inconsistencies.
Tirzepatide's GIP action may improve tolerability of GLP-1 side effects, though real-world differences are modest.

Tirzepatide made Eli Lilly briefly the most valuable pharmaceutical company in the world in 2023 — a molecule essentially printing money one weekly injection at a time.

If you want

You want maximum weight loss and have diabetes

Tirzepatide's dual mechanism consistently delivers ~5-7% more body weight lost in trials — the data is hard to argue with.

→ Pick Tirzepatide

If you want

You have established cardiovascular disease or history of heart attack/stroke

Semaglutide has the definitive SELECT trial proving a 20% reduction in major cardiovascular events — Tirzepatide's CV data is still maturing.

→ Pick Semaglutide

If you want

You're cost-sensitive or paying out of pocket

Semaglutide has more compounded options, manufacturer coupons, and is closer to generic availability — saving potentially hundreds per month.

→ Pick Semaglutide

If you want

You have obesity with heart failure (HFpEF)

Tirzepatide (Zepbound) is the first GLP-1 drug FDA-approved specifically for HFpEF — a unique and clinically meaningful distinction.

→ Pick Tirzepatide

Some links on this page are affiliate links. If you sign up through them, we may earn a commission at no extra cost to you.